

# Medications for Opioid Use Disorders

Amy S.B. Bohnert, Ph.D,

Department of Psychiatry, University of Michigan  
VA Center for Clinical Management Research



# What are Medications for Opioid Use Disorder (OUD)?




# Medication Assisted Treatment

## Comparison of Medications for Opioid Use Disorder (OUD)

	Methadone	Naltrexone	Buprenorphine
<b>Mechanism</b>	Agonist	Antagonist	Partial agonist
<b>Clinical uses</b>	Medically supervised withdrawal, maintenance	Prevention of relapse to opioid dependence, following medically supervised withdrawal	Medically supervised withdrawal, maintenance
<b>Administration</b>	Oral	Oral, intramuscular injection	Oral tablet or film, subdermal implant
<b>Prescribing and dispensing</b>	SAMHSA-certified Opioid Treatment Programs (OTPs) dispense methadone for daily administration on site or at home (stable patients).	Any individual licensed to prescribe medicines may prescribe and/or order administration by qualified staff.	Physicians outside OTPs must complete special training and certification to qualify for a federal waiver to prescribe. Any pharmacy can fill the script.
<b>Other considerations</b>	Stigma associated with treatment, potential for misuse/diversion	Lowers opioid tolerance and can increase overdose risk	<b>Potential for misuse/diversion</b>

## Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009

Robert P. Schwartz, MD, Jan Gryczynski, PhD, Kevin E. O'Grady, PhD, Joshua M. Sharfstein, MD, Gregory Warren, MA, MBA, Yngvild Olsen, MD, Shannon G. Mitchell, PhD, and Jerome H. Jaffe, MD



**FIGURE 1—Heroin overdose deaths and opioid agonist treatment: Baltimore, MD, 1995–2009.**

# Limited Access in Michigan

- Opioid Use Disorder: 9.2 residents per 1,000
- Optimistic Number of Treatment Slots: 5.3 patients per 1,000

# Primary care models for treating opioid use disorders: What actually works? A systematic review

Pooja Lagisetty , Katarzyna Klasa, Christopher Bush, Michele Heisler, Vineet Chopra, Amy Bohnert

Published: October 17, 2017 • <https://doi.org/10.1371/journal.pone.0186315>

## Successful Models for:


- Multi-disciplinary
- Coordinated Care
- AVPs as Care Managers
- Physician-centric
- “Hand offs” between clinics



Michigan Opioid Collaborative

[www.michiganopioidcollaborative.org](http://www.michiganopioidcollaborative.org)

Physicians



Communities







# 2020 Financial Incentives: Blue Cross Blue Shield of Michigan

## Practice Transformation

- Up to \$20,000 for practices
- Up to \$5,000 for Physician Organization per new practice

## Sustainability: Value Based Reimbursement

- 5% PCP
- 5% Specialist

## Care Team Development


- Billable through PDCM codes

RESEARCH LETTER

Pooja A. Lagisetty, MD, MSc  
Ryan Ross, BS  
Amy Bohnert, PhD  
Michael Clay, MD  
Donovan T. Maust, MD, MSc

# Buprenorphine Treatment Divide by Race/Ethnicity and Payment

Figure. Buprenorphine Visits by Race/Ethnicity and Payment Type, 2004-2015



Buprenorphine visits (n = 1369) and 95% CIs per 10 000 visits (shaded areas), grouped by year and stratified by race/ethnicity and payment type. Estimates account for complex survey design elements and are nationally representative.